Sanofi (SNY) KPIs and segments
Close on Nov 18, 2026Market cap $114.92BP/E 13.4Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Sanofi · năm tài chính kết thúc ngày 31 tháng 12
Nhìn nhanh KPI của Sanofi: 106 chỉ số vận hành, trong đó có Biopharma Net Sales, All Newly Launched Medicines & Vaccines và Pharma Launches Cohort, lấy từ 100 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Biopharma Net Sales(€M)8 | 14,444 | 11,597 | 10,509 | 11,303 | 12,434 | 9,994 | 9,895 | 10,564 | 12,157 | 9,427 | 8,933 | 9,687 | |
Constant Exchange Rate (CER) YoY Growth(%) | 14.3% | 17.8% | 13.6% | 13.3% | 7.0% | 10.1% | 9.7% | 10.3% | 16.7% | 10.4% | 6.5% | 9.3% | |
United States(€M) | 8,603 | 6,344 | 5,289 | 5,803 | 6,838 | 4,878 | 4,657 | 5,151 | 6,543 | 4,379 | 3,913 | 4,534 | |
Europe(€M) | 2,579 | 2,141 | 2,163 | 2,436 | 2,589 | 2,101 | 2,043 | 2,433 | 2,522 | 2,041 | 2,031 | 2,293 | |
Rest of World(€M) | 3,262 | 3,112 | 3,057 | 3,064 | 3,007 | 3,015 | 3,195 | 2,980 | 3,092 | 3,007 | 2,989 | 2,860 | |
Net Sales Invoiced in U.S. Dollar (USD Share)(%) | 60.4% | 56.0% | 51.0% | 52.4% | 56.2% | 49.9% | 48.0% | 50.0% | 52.5% | 45.5% | |||
Net Sales Invoiced in Euro (EUR Share)(%) | 15.3% | 16.2% | 17.8% | 19.2% | 17.6% | 18.8% | 17.7% | 20.2% | 18.6% | 19.5% | |||
Net Sales Invoiced in Chinese Yuan (CNY Share)(%) | 5.2% | 5.7% | 5.9% | 4.8% | 5.4% | 6.6% | 6.9% | 5.1% | 5.3% | 6.7% | 6.6% | 5.7% | |
Net Sales Invoiced in Japanese Yen (JPY Share)(%) | 2.4% | 3.0% | 2.8% | 3.0% | 2.7% | 3.7% | 3.5% | 3.4% | 3.0% | 3.6% | 3.7% | 3.7% | |
All Newly Launched Medicines & Vaccines ( incl. Beyfortus )(€M)4 | 2,176 | 1,530 | 1,517 | 1,816 | 1,805 | 969 | 1,131 | 1,668 | |||||
Pharma Launches Cohort (ALTUVIIIO, Nexviazyme, Rezurock, Xenpozyme, Tzield, Sarclisa, Ayvakit, Qfitlia, Wayrilz)(€M)4 | 1,390 | 1,305 | 1,171 | 1,121 | 1,046 | 897 | 847 | 827 | |||||
Dupixent (dupilumab — Immunology Flagship)(€M)4 | 5,687 | 5,154 | 4,170 | 4,246 | 4,156 | 3,832 | 3,480 | 3,458 | 3,476 | 3,303 | 2,835 | 2,990 | |
Constant Exchange Rate (CER) YoY Growth(%) | 34.8% | 37.6% | 30.8% | 32.2% | 26.2% | 21.1% | 20.3% | 16.0% | 23.8% | 29.2% | 24.9% | 31.3% | |
United States(€M) | 4,376 | 3,899 | 3,023 | 3,182 | 3,073 | 2,807 | 2,476 | 2,551 | 2,556 | 2,407 | 2,030 | 2,299 | |
Europe(€M) | 588 | 583 | 563 | 509 | 504 | 485 | 459 | 431 | 417 | 399 | 371 | 329 | |
Rest of World(€M) | 723 | 672 | 584 | 555 | 579 | 540 | 545 | 476 | 503 | 497 | 434 | 362 | |
Kevzara (sarilumab — Immunology)(€M)4 | 222 | 177 | 124 | 131 | 131 | 134 | 111 | 126 | 109 | 102 | 87 | 105 | |
Influenza & COVID-19 Vaccines (Fluzone High-Dose, Fluad, Flublok)(€M)4 | 1,256 | 54 | 67 | 575 | 1,525 | 141 | 73 | 454 | 1,913 | 115 | 73 | 741 | |
Constant Exchange Rate (CER) YoY Growth(%) | -18.8% | -61.7% | -4.1% | 31.5% | -16.8% | 26.1% | -1.4% | -36.8% | 10.9% | 20.2% | 38.1% | -4.0% | |
United States(€M) | 911 | -7 | 23 | 236 | 1,038 | 27 | 27 | 178 | 1,239 | 11 | 5 | 224 | |
Europe(€M) | 243 | 20 | 13 | 148 | 356 | 46 | 6 | 130 | 480 | 29 | 1 | 258 | |
Rest of World(€M) | 102 | 41 | 31 | 191 | 131 | 68 | 40 | 146 | 194 | 75 | 67 | 259 | |
Polio / Pertussis / Hib (PPH) & Booster Vaccines (Pentaxim, Hexaxim, Adacel)(€M)4 | 823 | 700 | 664 | 551 | 642 | 693 | 668 | 632 | 761 | 711 | 637 | 574 | |
Beyfortus (nirsevimab — RSV Infant Immunization)(€M)4 | 631 | 108 | 284 | 686 | 739 | 72 | 284 | 841 | 645 | 18 | 182 | 410 | |
Constant Exchange Rate (CER) YoY Growth(%) | -15.4% | 54.2% | 2.8% | -14.9% | 19.8% | 322.2% | 54.9% | 106.6% | 381.8% | ||||
United States(€M) | 240 | 19 | 46 | 266 | 389 | 3 | 65 | 420 | 532 | 2 | 114 | 315 | |
Europe(€M) | 266 | 7 | 80 | 255 | 261 | 7 | 78 | 335 | 98 | 0 | 7 | 95 | |
Rest of World(€M) | 125 | 82 | 158 | 165 | 89 | 62 | 141 | 86 | 15 | 16 | 61 | 0 | |
Meningitis, Travel & Endemic Vaccines (MenQuadfi, Rabies, Yellow Fever)(€M)4 | 476 | 287 | 278 | 227 | 451 | 307 | 302 | 249 | 484 | 297 | 286 | 263 | |
ALTUVIIIO (efanesoctocog alfa — Hemophilia A)(€M)4 | 408 | 349 | 325 | 324 | 294 | 291 | 251 | 230 | 172 | 158 | 122 | 94 | |
Constant Exchange Rate (CER) YoY Growth(%) | 37.8% | 23.7% | 42.2% | 53.0% | 81.4% | 91.8% | 100.0% | 143.6% | 278.3% | 772.2% | |||
United States(€M) | 345 | 305 | 271 | 276 | 247 | 238 | 218 | 198 | 160 | 144 | 115 | 92 | |
Europe(€M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Rest of World(€M) | 63 | 44 | 54 | 48 | 47 | 53 | 33 | 32 | 12 | 14 | 7 | 2 | |
Fabrazyme (agalsidase beta — Fabry Disease)(€M)4 | 260 | 258 | 265 | 252 | 242 | 263 | 262 | 269 | 253 | 273 | 252 | 242 | |
Nexviazyme / Nexviadyme (avalglucosidase alfa — Pompe Disease)(€M)4 | 211 | 218 | 208 | 203 | 200 | 192 | 195 | 184 | 163 | 168 | 152 | 131 | |
Ayvakit / Ayvakyt (avapritinib — Systemic Mastocytosis)(€M)3 | 203 | 190 | 177 | 168 | 137 | ||||||||
Sarclisa (isatuximab — Multiple Myeloma)(€M)4 | 196 | 187 | 167 | 157 | 155 | 140 | 136 | 130 | 114 | 121 | 106 | 103 | |
Cerezyme (imiglucerase — Gaucher Disease)(€M)4 | 173 | 166 | 186 | 171 | 161 | 173 | 190 | 171 | 164 | 193 | 214 | 133 | |
Alprolix (eftrenonacog alfa — Hemophilia B)(€M)4 | 172 | 163 | 119 | 149 | 149 | 145 | 160 | 169 | 148 | 141 | 130 | 142 | |
Rezurock (belumosudil — Chronic Graft-versus-Host Disease)(€M)4 | 165 | 163 | 133 | 113 | 114 | 132 | 131 | 132 | 131 | 114 | 93 | 86 | |
Myozyme / Lumizyme (alglucosidase alfa — Pompe Disease)(€M)4 | 105 | 108 | 112 | 122 | 122 | 140 | 135 | 132 | 168 | 180 | 191 | 159 | |
Cerdelga (eliglustat — Oral Gaucher Disease)(€M)4 | 95 | 94 | 89 | 83 | 86 | 80 | 86 | 87 | 81 | 82 | 83 | 75 | |
Aldurazyme (laronidase — MPS I)(€M)4 | 77 | 80 | 67 | 63 | 79 | 69 | 94 | 69 | 67 | 78 | 83 | 62 | |
Cablivi (caplacizumab — aTTP Rare Blood Disorder)(€M)4 | 70 | 85 | 68 | 69 | 66 | 69 | 67 | 73 | 63 | 54 | 59 | 58 | |
Jevtana (cabazitaxel — Prostate Cancer)(€M)4 | 67 | 70 | 66 | 60 | 62 | 66 | 75 | 77 | 73 | 72 | 68 | 76 | |
Xenpozyme (olipudase alfa — ASMD)(€M)4 | 63 | 64 | 63 | 61 | 57 | 54 | 56 | 38 | 41 | 37 | 35 | 26 | |
Eloctate (efmoroctocog alfa — Hemophilia A)(€M)4 | 45 | 84 | 58 | 63 | 77 | 65 | 70 | 81 | 96 | 105 | 86 | 103 | |
Tzield (teplizumab — Stage 2 Type 1 Diabetes Delay)(€M)4 | 42 | 23 | 14 | 16 | 18 | 18 | 11 | 18 | 15 | 11 | 10 | 10 | |
Wayrilz (rilzabrutinib — Immune Thrombocytopenia)(€M)3 | 19 | 17 | 10 | 6 | 1 | ||||||||
Qfitlia (fitusiran — Hemophilia A & B siRNA Prophylaxis)(€M)3 | 8 | 7 | 5 | 4 | 4 | 1 | 0 | ||||||
Lantus (insulin glargine 100 U/mL)(€M)4 | 530 | 394 | 419 | 419 | 438 | 426 | 450 | 439 | 430 | 399 | 360 | 276 | |
Constant Exchange Rate (CER) YoY Growth(%) | 18.5% | -7.0% | -0.7% | 1.1% | 6.7% | 11.5% | 24.4% | 63.4% | 33.4% | 21.0% | -15.4% | -24.9% | |
United States(€M) | 293 | 161 | 183 | 199 | 214 | 199 | 196 | 193 | 175 | 158 | 112 | 34 | |
Europe(€M) | 73 | 73 | 73 | 73 | 75 | 74 | 75 | 80 | 85 | 83 | 92 | 83 | |
Rest of World(€M) | 164 | 160 | 163 | 147 | 149 | 153 | 179 | 166 | 170 | 158 | 156 | 159 | |
Toujeo (insulin glargine 300 U/mL)(€M)4 | 430 | 354 | 375 | 332 | 321 | 338 | 354 | 290 | 303 | 313 | 321 | 278 | |
Constant Exchange Rate (CER) YoY Growth(%) | 31.2% | 4.4% | 10.5% | 18.6% | 9.2% | 10.5% | 10.0% | 6.5% | 18.1% | 11.0% | 18.0% | 11.4% | |
United States(€M) | 124 | 63 | 71 | 59 | 55 | 60 | 66 | 46 | 54 | 61 | 56 | 47 | |
Europe(€M) | 130 | 125 | 134 | 128 | 124 | 126 | 122 | 120 | 118 | 122 | 119 | 109 | |
Rest of World(€M) | 176 | 166 | 170 | 145 | 142 | 152 | 166 | 124 | 131 | 130 | 146 | 122 | |
Plavix (clopidogrel — Antiplatelet)(€M)4 | 206 | 216 | 224 | 214 | 223 | 229 | 244 | 211 | 230 | 235 | 238 | 254 | |
Lovenox (enoxaparin sodium — Low-Molecular-Weight Heparin)(€M)4 | 174 | 180 | 184 | 179 | 196 | 209 | 238 | 231 | 233 | 256 | 262 | 263 | |
Praluent (alirocumab — PCSK9 Inhibitor)(€M)4 | 156 | 164 | 153 | 132 | 127 | 137 | 130 | 110 | 126 | 126 | 121 | 118 | |
Thymoglobulin (anti-thymocyte globulin — Transplant)(€M)4 | 134 | 137 | 120 | 124 | 118 | 126 | 122 | 125 | 121 | 129 | 117 | 112 | |
Aprovel / Avapro (irbesartan — Hypertension)(€M)4 | 103 | 114 | 104 | 105 | 100 | 102 | 110 | 105 | 98 | 108 | 105 | 106 | |
Soliqua / Suliqua (insulin glargine + lixisenatide)(€M)4 | 93 | 86 | 79 | 84 | 62 | 66 | 70 | 58 | 55 | 56 | 58 | 61 | |
Multaq (dronedarone — Atrial Fibrillation)(€M)4 | 93 | 71 | 80 | 76 | 78 | 79 | 81 | 77 | 72 | 84 | 78 | 87 | |
Apidra (insulin glulisine)(€M)4 | 69 | 70 | 70 | ||||||||||
Synvisc / Synvisc-One (hylan G-F 20 — Viscosupplementation)(€M)4 | 47 | 58 | 35 | ||||||||||
Industrial Sales (Active Ingredients & Third-Party Manufacturing)(€M)1 | 89 | 109 | 81 | 136 | 96 | 148 | 103 | 124 | 125 | 117 | 157 | 166 | |
Clinical Pipeline Projects (Phase 1 to Registration)1 | 61 | 61 | 77 | 80 | 94 | 82 | 86 | 83 | 78 | 78 | 77 | ||
Potential New Medicines & Vaccines (NMEs / NVEs in Clinical Development) | 36 | 36 | 40 | 40 | 44 | 40 | 41 | 38 | 36 | 38 | 39 | ||
Global Health Unit (GHU) Active Local Healthcare Partnerships3 | 86 | 99 | 95 | 87 | 83 | 83 | 85 | 44 | |||||
GHU Countries Reached | 37 | 35 | 26 | 34 | 31 | 29 | 21 | 18 | |||||
GHU Impact Fund Active Investments | 9 | 8 | 8 | 8 | 8 | 7 | 7 | 4 | |||||
Pipeline Assets Covered by Global Access Plans | 13 | 13 | 13 | 13 | 12 | 12 | 12 | ||||||
Business Gross Profit(€M)1 | 11,698 | 9,411 | 8,188 | 8,518 | 9,815 | 7,742 | 7,718 | 7,844 | 9,317 | 7,169 | 6,761 | 7,443 | |
Business Gross Margin (% of Net Sales)(%) | 81.0% | 81.2% | 77.9% | 75.4% | 78.9% | 77.5% | 78.0% | 74.3% | |||||
Business Operating Income (BOI)(€M)2 | 5,430 | 3,291 | 2,967 | 2,341 | 4,445 | 2,461 | 2,902 | 2,078 | 4,327 | 2,521 | 2,417 | 2,356 | |
Business Operating Income Margin (% of Net Sales)(%) | 37.6% | 28.4% | 28.2% | 20.7% | 35.7% | 24.6% | 29.3% | 19.7% | |||||
Biopharma Segment BOI Margin(%) | 37.4% | 28.2% | 28.1% | 20.7% | 35.7% | 24.6% | 29.2% | 19.3% | |||||
Business Net Income(€M)1 | 4,255 | 2,501 | 2,264 | 1,856 | 3,547 | 1,940 | 2,212 | 1,642 | 3,411 | 1,951 | 1,908 | 1,935 | |
Business Net Income Margin (% of Net Sales)(%) | 29.5% | 21.6% | 21.5% | 16.4% | 28.5% | 19.4% | 22.4% | 15.5% | 28.1% | 20.7% | 21.4% | 20.0% | |
Business Earnings per Share (Business EPS)(€) | 3.55 | 2.09 | 1.88 | 1.53 | 2.91 | 1.59 | 1.79 | 1.31 | |||||
Free Cash Flow (Non-IFRS)(€M)1 | 3,269 | 2,670 | 1,054 | 2,637 | 2,994 | 1,429 | 1,029 | 2,340 | 3,187 | 862 | |||
Closing Net Debt(€M) | 12,201 | 15,513 | 12,900 | 11,008 | 11,057 | 5,102 | 11,245 | 8,772 | 11,483 | 15,112 | 8,534 | 7,793 | |
Property, Plant & Equipment (Net Carrying Value by Asset Class & Geography)(€M) | 10,508 | 10,364 | 10,157 | 10,052 | 9,698 | 9,574 | 9,819 | 10,091 | 10,160 | ||||
Women in Senior Leadership Roles(%) | 49.0% | 48.0% | 48.0% | 47.0% | 47.0% | 46.0% | 46.0% | ||||||
Women in Executive Committee / Executive Roles(%) | 44.0% | 44.0% | 44.0% | 44.0% | 44.0% | 44.0% | 43.0% | 43.0% | |||||
Sanofi Strategic U.S.-Listed Biotech Equity Portfolio Value (Form 13F-HR)($M)9 | 630 | 534 | 336 | 310 | 260 | 176 | 166 | 174 | |||||
Disclosed U.S.-Listed Biotech Equity Positions | 16 | 10 | 9 | 8 | 9 | 10 | 9 | 9 | |||||
Novavax, Inc. Position Value($M) | 74.4 | 64.8 | 56.0 | 46.2 | 59.7 | 43.4 | 44.1 | 55.3 | |||||
AnaptysBio, Inc. Position Value($M) | 41.3 | 55.5 | 30.4 | 39.9 | 25.2 | 18.3 | 15.3 | 10.9 | |||||
Inhibrx Biosciences, Inc. Position Value($M) | 116 | 110 | 77.9 | 91.5 | 39 | 16.5 | 16.2 | 17.8 | |||||
MeiraGTx Holdings plc Position Value($M) | 134 | 165 | 106 | 97.0 | 100 | 79.5 | 82.7 | 74.3 | |||||
Immuneering Corporation Position Value($M) | 11.1 | 13.5 | 14.3 | 17.8 | 19.0 | ||||||||
MapLight Therapeutics, Inc. Position Value($M) | 9.29 | 32.7 | 18.5 | 16.0 | |||||||||
Agomab Therapeutics NV Position Value($M) | 30.9 | 36.1 | 29.2 | ||||||||||
Q32 Bio Inc. Position Value($M) | 2.02 | 3.11 | 1.57 | 0.81 | 0.48 | 0.36 | 0.40 | 0.84 | |||||
U.S. Federal Prime Contract Obligations to Sanofi Entities (Monthly / Quarterly / Annual)($M)4 | 5.92 | -11.9 | 40 | -2.31 | 43.2 | 4.46 | 24.0 | 1.02 | 32.8 | 3.93 | 18.6 | 3.74 | |
Department of Health & Human Services (CDC Vaccines for Children & BARDA)($M) | 5.84 | -12.1 | 30.7 | -2.84 | 42.8 | 3.74 | 8.64 | 0.30 | 32.2 | 1.19 | 11.5 | 2.96 | |
Department of Veterans Affairs (Pharmaceutical & Vaccine Supply)($M) | 0 | 0.04 | 0.23 | 0 | 0 | 0 | 0 | 0.10 | 0 | 2.59 | 3.73 | 0.02 | |
Department of Defense (Defense Logistics Agency Immunization Supply)($M) | 0 | 0.11 | 8.75 | 0.49 | 0.15 | 0.25 | 15.5 | 0.56 | 0.08 | 0.06 | 2.68 | 0.61 | |
Department of State($M) | 0.07 | -0.06 | 0 | 0 | 0.25 | 0.34 | 0.01 | 0.02 | 0.58 | 0 | 0.14 | 0.10 | |
ECB Reference Exchange Rate — U.S. Dollar per Euro (USD / EUR)4 | 1.15 | 1.16 | 1.17 | 1.16 | 1.17 | 1.13 | 1.05 | 1.07 | 1.10 | 1.08 | 1.09 | 1.08 | |
Chinese Yuan per Euro (CNY / EUR) | 7.76 | 7.91 | 8.10 | 8.25 | 8.36 | 8.20 | 7.66 | 7.68 | 7.87 | 7.80 | 7.80 | 7.77 | |
Japanese Yen per Euro (JPY / EUR) | 183.25 | 185.34 | 183.60 | 179.22 | 172.29 | 163.81 | 160.45 | 162.55 | 163.95 | 167.77 | 161.15 | 159.12 | |
Indian Rupee per Euro (INR / EUR) | 109.98 | 110.10 | 107.12 | 103.64 | 102.00 | 97.05 | 91.14 | 90.18 | 92.01 | 89.82 | 90.16 | 89.51 | |
British Pound per Euro (GBP / EUR) | 0.86 | 0.87 | 0.87 | 0.88 | 0.87 | 0.85 | 0.84 | 0.83 | 0.85 | 0.85 | 0.86 | 0.87 | |
U.S. Producer Price Index — Pharmaceutical Preparation Manufacturing (NAICS 325412)2 | 929.30 | 926.20 | 926.00 | 919.30 | 918.70 | 914.80 | 916.50 | 918.50 | 918.10 | 914.00 | 909.00 | 896.40 | |
IFRS Net Sales(€M)2 | 14,444 | 11,597 | 10,509 | 11,303 | 12,434 | 9,994 | 9,895 | 10,564 | 12,157 | 9,427 | 8,933 | 9,687 | |
Other Revenues (VaxServe Distribution & Royalties)(€M) | 789 | 703 | 735 | 902 | 736 | 741 | 711 | 856 | 820 | 736 | 793 | 1,381 | |
Cost of Sales(€M) | 3,632 | 3,017 | 3,138 | 3,756 | 3,412 | 2,993 | 2,889 | 3,576 | 3,663 | 2,997 | 2,969 | 3,629 | |
IFRS Gross Profit(€M) | 11,601 | 9,283 | 8,106 | 8,449 | 9,758 | 7,742 | 7,717 | 7,844 | 9,314 | 7,166 | 6,757 | 7,439 | |
Research & Development Expenses (IFRS)(€M) | 1,849 | 2,233 | 1,747 | 2,291 | 1,834 | 1,909 | 1,808 | 2,257 | 1,802 | 1,665 | 1,670 | 1,815 | |
Selling & General Expenses (IFRS)(€M) | 2,309 | 2,465 | 2,327 | 2,746 | 2,291 | 2,284 | 2,222 | 2,648 | 2,232 | 2,192 | 2,111 | 2,466 | |
Amortization of Intangible Assets(€M)1 | 556 | 552 | 535 | 538 | 461 | 378 | 399 | 450 | 401 | 414 | 484 | 496 | |
IFRS Operating Income(€M)1 | 4,349 | 1,047 | 2,121 | -1,038 | 3,623 | 1,473 | 2,285 | 945 | 3,539 | 1,532 | 1,236 | 384 | |
IFRS Net Income Attributable to Equity Holders of Sanofi(€M)1 | 3,021 | 343 | 1,614 | -801 | 2,802 | 3,939 | 1,872 | 499 | 2,815 | 1,113 | 1,133 | -555 | |
IFRS Basic Earnings per Share(€)1 | 2.52 | 0.29 | 1.34 | -0.66 | 2.30 | 3.24 | 1.52 | 0.40 | 2.25 | 0.89 | 0.91 | -0.44 | |
Total Assets(€M)4 | 130,287 | 129,060 | 128,024 | 126,805 | 129,794 | 124,959 | 131,892 | 132,798 | 126,464 | ||||
Total Liabilities4 | |||||||||||||
Equity Attributable to Equity Holders of Sanofi(€M)1 | 72,879 | 69,207 | 72,808 | 71,376 | 73,263 | 70,008 | 74,074 | 77,507 | 74,040 | ||||
IFRS Net Cash Provided by Operating Activities(€M)2 | 3,871 | 2,960 | 1,683 | 3,445 | 3,750 | 1,462 | 2,093 | 3,811 | 3,848 | 1,334 | 88 | ||
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Sanofi reports consolidated financial and commercial operating results under IFRS in millions of euros (€M) and euros per share (€), with fiscal years ending December 31.
- Following the separation of Opella (Consumer Healthcare), continuing commercial operations reflect Sanofi's pure-play Biopharma perimeter across Immunology, Vaccines, Rare Diseases, Rare Blood Disorders, Neurology, Oncology, and General Medicines.
- Constant Exchange Rate (CER) growth rates are published directly by Sanofi and represent the primary basis on which management issues full-year net sales and Business EPS guidance.
- Where cash flow items are published only on a cumulative year-to-date basis in Form 6-K Appendix 5 (IFRS Operating Cash Flow, PP&E and Software CapEx, Share Repurchases), standalone quarters are derived strictly by subtracting the prior cumulative period within the same reporting basis; standalone quarterly Free Cash Flow is taken directly as reported on Page 1 of each Form 6-K release.
- Parent-only statutory financial statements of Sanofi S.A. in the French Universal Registration Document are prepared annually under French GAAP for a holding entity and are not comparable to quarterly IFRS consolidated statements; no consolidated-minus-parent subtraction is performed.
Không hiện vì thiếu các kỳ gần đây (10)
- Opella Consumer Healthcare Segment — reclassified to discontinued operations from 2024 and deconsolidated in 2025 upon sale of a controlling stake (with Sanofi's retained 48.2% interest captured under equity-accounted associates).
- Commercial Medicine Prescription Counts, Vial Volumes & Treated Patient Counts (e.g., Dupixent '>1.3 million patients') — Sanofi reports commercial medicines strictly in €M net sales and CER %, while patient reach remarks in earnings calls are disclosed only as approximate lower bounds ('more than', 'over') rather than exact continuous series.
- Cumulative Year-to-Date Patient Reach in Form 6-K Sustainability Appendix (GHU YTD Patients Treated & Access Diabetes YTD Patients) — cumulative YTD unique-patient counts cannot be subtracted across quarters without misstating quarterly active patients; annual de-duplicated GHU NCD patient counts from the CSRD workbook are shown instead.
- Target Disease Epidemiology Patient Populations (July 2026 IR Epidemiology Update) — point-in-time 2026 disease prevalence and biologic-eligible population estimates without historical multi-year time series.
- AMF Monthly Share Repurchase Reports — monthly disclosures cover February 2025 through April 2026 only, with no monthly share buyback filings for August–October 2026 after completion of the buyback tranche (quarterly share repurchase cash outflows are included through Q3 2026).
- SEC Form SD Conflict Minerals Supplier Metrics — narrative compliance disclosures without multi-year comparable numeric smelter/supplier tables.
- Legacy De-Materialized Products (e.g., Aubagio following 2023 loss of exclusivity) — ceased standalone quarterly table disclosure in 2026 IR sales databooks.
- Biopharma Net Sales — Geography, Launch Cohorts, Immunology, Vaccines & Specialty › Ayvakit / Ayvakyt (avapritinib — Systemic Mastocytosis) › Constant Exchange Rate (CER) YoY Growth — fewer than 3 consecutive latest quarters/months (or 2 latest fiscal years) reported
- Biopharma Net Sales — Geography, Launch Cohorts, Immunology, Vaccines & Specialty › Wayrilz (rilzabrutinib — Immune Thrombocytopenia) › Constant Exchange Rate (CER) YoY Growth — fewer than 3 consecutive latest quarters/months (or 2 latest fiscal years) reported
- Biopharma Net Sales — Geography, Launch Cohorts, Immunology, Vaccines & Specialty › Qfitlia (fitusiran — Hemophilia A & B siRNA Prophylaxis) › Constant Exchange Rate (CER) YoY Growth — fewer than 3 consecutive latest quarters/months (or 2 latest fiscal years) reported
Dữ liệu cập nhật 2026-11-07.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Biopharma Net Sales — Geography, Launch Cohorts, Immunology, Vaccines & Specialty
- Biopharma Net Sales (€M)15 kỳ
- All Newly Launched Medicines & Vaccines ( incl. Beyfortus ) (€M)8 kỳ
- Pharma Launches Cohort (ALTUVIIIO, Nexviazyme, Rezurock, Xenpozyme, Tzield, Sarclisa, Ayvakit, Qfitlia, Wayrilz) (€M)8 kỳ
- Dupixent (dupilumab — Immunology Flagship) (€M)23 kỳ
- Kevzara (sarilumab — Immunology) (€M)23 kỳ
- Influenza & COVID-19 Vaccines (Fluzone High-Dose, Fluad, Flublok) (€M)23 kỳ
- Polio / Pertussis / Hib (PPH) & Booster Vaccines (Pentaxim, Hexaxim, Adacel) (€M)15 kỳ
- Beyfortus (nirsevimab — RSV Infant Immunization) (€M)15 kỳ
- Meningitis, Travel & Endemic Vaccines (MenQuadfi, Rabies, Yellow Fever) (€M)15 kỳ
- ALTUVIIIO (efanesoctocog alfa — Hemophilia A) (€M)15 kỳ
- Fabrazyme (agalsidase beta — Fabry Disease) (€M)23 kỳ
- Nexviazyme / Nexviadyme (avalglucosidase alfa — Pompe Disease) (€M)19 kỳ
- Ayvakit / Ayvakyt (avapritinib — Systemic Mastocytosis) (€M)5 kỳ
- Sarclisa (isatuximab — Multiple Myeloma) (€M)23 kỳ
- Cerezyme (imiglucerase — Gaucher Disease) (€M)23 kỳ
- Alprolix (eftrenonacog alfa — Hemophilia B) (€M)23 kỳ
- Rezurock (belumosudil — Chronic Graft-versus-Host Disease) (€M)19 kỳ
- Myozyme / Lumizyme (alglucosidase alfa — Pompe Disease) (€M)23 kỳ
- Cerdelga (eliglustat — Oral Gaucher Disease) (€M)23 kỳ
- Aldurazyme (laronidase — MPS I) (€M)23 kỳ
- Cablivi (caplacizumab — aTTP Rare Blood Disorder) (€M)23 kỳ
- Jevtana (cabazitaxel — Prostate Cancer) (€M)23 kỳ
- Xenpozyme (olipudase alfa — ASMD) (€M)15 kỳ
- Eloctate (efmoroctocog alfa — Hemophilia A) (€M)23 kỳ
- Tzield (teplizumab — Stage 2 Type 1 Diabetes Delay) (€M)15 kỳ
- Wayrilz (rilzabrutinib — Immune Thrombocytopenia) (€M)5 kỳ
- Qfitlia (fitusiran — Hemophilia A & B siRNA Prophylaxis) (€M)7 kỳ
General Medicines (Diabetes, Cardiovascular & Transplant) & Industrial Sales
- Lantus (insulin glargine 100 U/mL) (€M)23 kỳ
- Toujeo (insulin glargine 300 U/mL) (€M)23 kỳ
- Plavix (clopidogrel — Antiplatelet) (€M)23 kỳ
- Lovenox (enoxaparin sodium — Low-Molecular-Weight Heparin) (€M)23 kỳ
- Praluent (alirocumab — PCSK9 Inhibitor) (€M)23 kỳ
- Thymoglobulin (anti-thymocyte globulin — Transplant) (€M)23 kỳ
- Aprovel / Avapro (irbesartan — Hypertension) (€M)23 kỳ
- Soliqua / Suliqua (insulin glargine + lixisenatide) (€M)23 kỳ
- Multaq (dronedarone — Atrial Fibrillation) (€M)23 kỳ
- Apidra (insulin glulisine) (€M)3 kỳ
- Synvisc / Synvisc-One (hylan G-F 20 — Viscosupplementation) (€M)3 kỳ
- Industrial Sales (Active Ingredients & Third-Party Manufacturing) (€M)23 kỳ
R&D Pipeline, Clinical Trials, Regulatory Quality & Global Patient Access
- Clinical Pipeline Projects (Phase 1 to Registration)11 kỳ
- Active Interventional Clinical Trials3 kỳ
- Subjects Enrolled in Interventional Clinical Trials3 kỳ
- Peer-Reviewed Scientific Publications Indexed on PubMed3 kỳ
- Completed Clinical Trials with Publicly Shared Results & Anonymized Data3 kỳ
- Global Health Unit (GHU) Active Local Healthcare Partnerships8 kỳ
- GHU Non-Communicable Disease (NCD) Patients Treated Annually3 kỳ
- Humanitarian Rare Disease Program — Medicine Vials Donated3 kỳ
- Compassionate Use / Managed Access Individual Patient Requests3 kỳ
- Health Authority GxP Regulatory Inspections Across Global Sites3 kỳ
- Class I / Critical Product Recalls3 kỳ
- Individual Case Safety Reports Submitted On Time to Authorities (%)3 kỳ
Gross-to-Net Pricing Deductions, Wholesaler Concentration & R&D / Regeneron Alliances
- Top 3 U.S. Pharmaceutical Wholesalers Share of Consolidated Net Sales (%)6 kỳ
- Gross-to-Net Revenue Deductions Charged Against Gross Sales (€M)7 kỳ
- Gross-to-Net Rebates & Chargebacks Settled / Paid (€M)7 kỳ
- Ending Gross-to-Net Accrued Rebate & Chargeback Liability Reserve (€M)10 kỳ
- Regeneron Alliance — Net Profit-Sharing & Reimbursement Outflow (€M)3 kỳ
- Off-Balance-Sheet R&D Collaboration Commitments — Research-Phase Projects (€M)8 kỳ
- Off-Balance-Sheet R&D Contingent Development & Regulatory Milestones (€M)6 kỳ
- Off-Balance-Sheet Asset-Acquisition Contingent Milestones (€M)2 kỳ
- Other R&D Licensing & Collaboration Commitments (€M)6 kỳ
- Business Combination Contingent Consideration Liabilities (Fair Value) (€M)10 kỳ
Business Operating Performance (Non-IFRS), Free Cash Flow & Net Debt
Manufacturing Capacity (PP&E), Inventory by Stage, Drug Intangibles & Supply Chain
- Inventories (Net Carrying Value) (€M)11 kỳ
- Property, Plant & Equipment (Net Carrying Value by Asset Class & Geography) (€M)11 kỳ
- Property, Plant & Equipment (Gross Historical Cost) (€M)10 kỳ
- Biopharma Capital & Intangible Asset Additions (€M)7 kỳ
- Other Intangible Assets — Principal Acquired Medicines & Platforms (Net) (€M)11 kỳ
- External Supplier Procurement Spend3 kỳ
Workforce, Compensation, Pensions & Environmental Sustainability
- Women in Senior Leadership Roles (%)7 kỳ
- Women in Executive Committee / Executive Roles (%)8 kỳ
- Global Employees (Year-End Headcount)11 kỳ
- Total Employee Benefits Expense (€M)11 kỳ
- Defined Benefit Pension & Post-Employment Benefit Obligation (€M)8 kỳ
- Total Recordable Injury Rate (TRIR per Million Hours Worked) (×)3 kỳ
- Employees Trained on Code of Conduct & Business Ethics3 kỳ
- Total Site Energy Consumption4 kỳ
- Total Greenhouse Gas Emissions — Scope 1, 2 (Market-Based) & Scope 34 kỳ
- Total Water Withdrawal4 kỳ
- Total Operational Waste Generated4 kỳ
- Environmental Site Remediation Provisions (€M)4 kỳ
Sanofi U.S. LLC — Audited Employee Savings Plans (SEC Form 11-K)
Aventis Pharma Limited (Sanofi UK Statutory Filings), Associate Stakes & 13F Biotech Portfolio
External Benchmarks — U.S. Federal Vaccine Obligations, ECB FX & BLS Drug Price Indices
Consolidated IFRS Financial Statements & Segment Baseline
- IFRS Net Sales (€M)15 kỳ
- IFRS Gross Profit (€M)15 kỳ
- Research & Development Expenses (IFRS) (€M)15 kỳ
- Selling & General Expenses (IFRS) (€M)15 kỳ
- Amortization of Intangible Assets (€M)12 kỳ
- IFRS Operating Income (€M)15 kỳ
- IFRS Net Income Attributable to Equity Holders of Sanofi (€M)15 kỳ
- IFRS Basic Earnings per Share (€)12 kỳ
- Total Assets (€M)11 kỳ
- Total Liabilities (€M)0 kỳ
- Equity Attributable to Equity Holders of Sanofi (€M)11 kỳ
- IFRS Net Cash Provided by Operating Activities (€M)11 kỳ
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Sanofi
- Sanofi Q3 2026 Net Sales Workbook (2026_10_30_Sanofi_Q3_2026_SALES_EN.xlsx) ↗
- Sanofi Q4 2025 Net Sales Workbook (2026_01_29_Sanofi_Q4_FY_2025_SALES_EN.xlsx) ↗
- Sanofi Q3 2026 Earnings Release Form 6-K (filed 2026-10-30) ↗
- Sanofi Q4 2025 Earnings Release Form 6-K (filed 2026-01-29) ↗
- Sanofi 2025 ESG Key Performance Indicators Databook (CSRD / ESRS) ↗
- Sanofi Form 20-F FY2025 Inline XBRL (filed 2026-02-17) ↗
- USAspending.gov — U.S. Federal Prime Contract Obligations (HHS/CDC, DoD, VA) ↗
- European Central Bank (ECB) — Official Euro Foreign Exchange Reference Rates ↗
- U.S. BLS PPI — Pharmaceutical Preparation Manufacturing (PCU325412325412) ↗
- Sanofi U.S. Group Savings Plan Form 11-K Inline XBRL (filed 2026-06-30) ↗
- Sanofi Puerto Rico Savings Plan Form 11-K Inline XBRL (filed 2026-06-30) ↗
- UK Gov Gender Pay Gap Service — Aventis Pharma Limited (Sanofi UK, Co. No. 01535640) ↗
See a number that looks wrong?